


Remarks

The specification has been amended to update the "Cross-Reference to Related Applications".

The claims have been amended to cancel claims 5-6 and 11-12 without prejudice and to amend independent claims 1 and 7 to limit the anti-diabetic agent to a specific list of agents. In addition, Claims 8-10 have been amended to depend from Claim 7. Support for the amendment to Claims 1 and 7 is found on page 10, line 26 to page 11, line 2 of the specification as filed. Applicant therefore maintains that the amendment does not add new matter and is fully supported by the specification as filed. After entry of the amendment, Claims 1-4 and 7-10 will remain pending and under consideration.

Early favorable action is respectfully requested.

Respectfully submitted,



Mary A. Appollina  
Reg. No. 34,087  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-3742  
DATED: January 23, 2004